Abstract Library

#3728 ACTH-secreting pancreatic neuroendocrine neoplasms – A case-series

Introduction: Ectopic Cushing’s syndrome occurs rarely in patients with pancreatic neuroendocrine neoplasms. Early recognition of symptoms is critical given the high morbidity and mortality associated with Cushing’s syndrome.

Conference:

Presenting Author: Al-Toubah T

Authors: Al-Toubah T, Pelle E, Hallanger-Johnson J, Haider M, Strosberg J,

Keywords: pancreatic neuroendocrine neoplasm, Cushing’s syndrome, ACTH, ectopic Cushing’s, neuroendocrine tumor,

#3722 A novel and potent Pb-212 alpha-particle therapy for NETs – Complete responses in mouse models to global clinical translation for NET patients

Introduction: A novel SSTR2 targeted peptide (VMT-alpha-NET) has been developed. Promising preclinical data have led to the initiation of multiple Phase 1 clinical trials in the United States for Pb-203 image-guided Pb-212 based alpha-particle therapy for NETs.

Conference:

Presenting Author: Schultz M

Authors: Schultz M, Johnson F, Li M, Liu D, McDonald M,

Keywords: NET, neuroendocrine tumor, alpha therapy, Pb-212, Pb-203, SPECT,

#3644 N-terminal pro-brain natriuretic peptide and chromogranin A as biomarkers for detection of carcinoid heart disease

Introduction: Carcinoid heart disease (CHD) is a serious complication for patients with neuroendocrine tumors (NETs), and early detection is crucial.

Conference:

Presenting Author: Lau T

Authors: Lau T, Johnson K, Oksjoki R, Baunwall S, Villadsen G,

Keywords: carcinoid heart disease, probnp, 5-hiaa, cga, biomarker,

#3334 Utility of midpoint imaging in patients receiving peptide receptor radionuclide therapy (PRRT) for advanced progressive midgut neuroendocrine tumors (NET)

Introduction: The NETTER-1 trial formed the basis for standard practice of PRRT, consisting of 4 cycles with follow-up imaging during midtreatment and after completion to evaluate disease response. However, in clinical practice the timing of midpoint imaging varies if performed at all, and it is unclear how often it influences subsequent management.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Norman A, Wee C, Hobday T, Kendi A, Johnson G,

Keywords: midpoint imaging, PRRT, clinical decision making,

#3173 Intestinal obstruction (IO) in patients receiving peptide receptor radionuclide therapy (PRRT) for gastro-enteropancreatic neuroendocrine tumors (GEP-NETs): Potential predictors and association with overall survival (OS)

Introduction: There are concerns for the risk of IO in patients with GEPNETs, especially in cases with peritoneal metastases or mesenteric vascular encasement.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Badawy M

Authors: Badawy M, Hobday T, Johnson G, Halfdanarson T, Young J,

Keywords: gastrointestinal NETs, PRRT (Lu-DOTATATE), intestinal obstruction, overall survival,